Annex 3.3. Maja Krajinovic’s CV
CURRICULUM VITAE
MAJA KRAJINOVIC
Associate Professor
Departments of Pediatrics & Pharmacology
University of Montreal
CHU Sainte-Justine
3175, chemin de la Côte-Sainte-Catherine
Montreal, Quebec H3T 1C5
Tel. (514) 345-4931 ext. 6259
E-mail: maja.krajinovic@umontreal.ca
Studies and Degrees
1988-1991
|
Ph.D.
|
Molecular Biology
|
Institute of Biology and Human Genetics and Institute of Molecular Genetics and Genetic Engineering, Medical Faculty, University of Belgrade: Human papilloma virus: frequency and role in the cervical cancer
|
1984-1986
|
M.Sc.
|
Medical Genetics
|
Institute of Biology and Human Genetics, Medical Faculty, University of Belgrade Prenatal diagnosis in the first trimester of pregnancy
|
1982-1984
|
Medical License
|
General Medical Training
|
Medical Faculty, University of Belgrade
|
1977-1982
|
M.D.
|
|
Medical Faculty, University of Belgrade
|
Academic Positions and Hospital Appointments
Associate Professor
|
2006-
|
Dept. of Pharmacology, University of Montreal (secondary affiliation)
|
Associate Professor
|
2006-
|
Dept. of Pediatrics, University of Montreal
|
Assistant Professor
|
2002-2006
|
Dept. of Pharmacology, University of Montreal (secondary affiliation)
|
Assistant Professor
|
2000-2006
|
Dept. of Pediatrics, University of Montreal
|
Scientist
|
2000-
|
Division of Hematology-Oncology, Research Center, St-Justine Hospital
|
Assistant Professor
|
1993-1998
|
Institute of Biology and Human Genetics, Medical Faculty, University of Belgrade, Yugoslavia
|
Research Associate
|
1998-2000
|
Division of Hematology-Oncology, Research Center, St-Justine Hospital
|
Teaching Assistant
|
1984-1992
|
Institute of Biology and Human Genetics, Medical Faculty, University of Belgrade
|
Research Training
1995-1998
|
Postdoctoral training
|
Division of Hematology-Oncology, Research Center, St-Justine Hospital
|
1992-1995
|
Postdoctoral training
|
International Centre for Genetic Engineering and Biotechnology (ICGEB)/UNIDO, Trieste, Italy
|
1990, 1992
|
Visiting Scientist
|
German Cancer Research Centre, Heidelberg, Germany
|
1998
|
Visiting Scientist
|
Department of Pediatrics, Guy’s Hospital, London
|
Scholarships and Distinctions
2007-2011
|
Scholarship
|
FRSQ, National
|
2003-2007
|
Scholarship
|
FRSQ, senior
|
2001-2003
|
Scholarship
|
FRSQ, junior II
|
2000-2001
|
Scholarship
|
Relève 2000, Faculté de Médecine, University of Montreal
|
1998-2000
|
Fellowship
|
St-Justine Hospital Foundation
|
1999
|
Scholar Award for Promising Clinical or Translational Cancer Research
|
Glaxo Wellcome Oncology, AACR 1999 meeting
|
1995-1998
|
Fellowship
|
Charles-Bruneau Foundation
|
1994-1995
|
Fellowship
|
Telethon, Italy
|
1993-1994
|
Fellowship
|
Heart Foundation, Italy
|
1978-1981
|
Best Medical Student Awards
|
University of Belgrade
|
Published Refereed Papers (2003-present)
-
Fleury I, Beaulieu P, Primeau M, Labuda D, Sinnett D, Krajinovic M (2003) Characterization of BCL-1 polymorphism in the glucocorticoid receptor gene. Clin Chem. 49:1528-1531.
-
Krajinovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, Théorêt Y, Moghrabi A and Sinnett D (2004) Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 103:252-257.
-
Costea I, Moghrabi A, Krajinovic M (2003) The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukemia. Pharmacogenetics 13:577-580.
-
Mathonnet G, Krajinovic M, Labuda D, and Sinnett D (2003) Role of DNA mismatch repair genetic polymorphisms in the risk of childhood acute lymphoblastic leukemia. Br J Haematol. 123:45-48.
-
Mathonnet G, Labuda D, Meloche C, Wambach T, Krajinovic M and Sinnett D (2003) Variable continental distribution of polymorphisms in the coding regions of DNA-repair genes. J Hum Genet. 48:659-664.
-
Krajinovic M, Lemieux-Blanchard É, Chiasson S, Primeau M, Costea I and Moghrabi A (2004) Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 4:66-72.
-
Fleury I, Primeau M, Doreau A, Costea I, Moghrabi A, Sinnett D and Krajinovic M (2004) Polymorphisms in genes relevant for corticosteroid response and the outcome of childhood acute lymphoblastic leukemia. Am J Pharmacogenomics. 4(5):331-341.
-
Brukner I, Paquin B, Belouchi M, Labuda D and Krajinovic M (2005) Decrease of self-priming by modified random oligonucleotides incresase the performance of whole genome amplification. Anal Biochem. 339(2):345-7.
-
Krajinovic M, Robaey P, Chiasson S, Lemieux-Blanchard E, Rouillard M and Moghrabi A (2005) The polymorphism in genes encoding the enzymes of homocysteine pathway and IQ score following the treatment for childhood acute lymphoblastic leukemia. Pharmacogenomics. 6 (3):293-302.
-
Krajinovic M, Costea I, Primeau M, Lemieux-Blanchard É, Chiasson S, Moghrabi A (2005). Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J. 5(6):374-380.
-
Thirumaran RK, Gast A, Flohr T, Burwinkel B, Bartram C, Hemminki K, Kumar R, Sinnett D, Labuda D and Krajinovic M (2005) MTHFR genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Blood 106:2590-1.
-
Krajinovic M (2005) Further insight into the role of NQO1 in childhood leukemia. Haematologica 90(11):1445.
-
Brukner I, Labuda D and Krajinovic M (2006) Phi-29-based amplification of small genomes. Anal Biochem. 354 (1): 154-156.
-
Todorovic Z, Dzocic E, Novakovic I, Mickovic D, Stojanovic R, Nesik Z, Krajinovic M, Prostrau M and Kostic V (2006) Homocysteine serum levels MTHFR C677T genotypes in patients with Parkinson’s disease with and without levodopa therapy. J Neurol Sci. 248 (1-2) :56-61
-
Costea I, Moghrabi A, Laverdiere C, Graziani A and Krajinovic M (2006) Folate cycle gene variants and chemotherapy toxicity in pediatric patients with ALL. Hematologica. 91 (8): 1113-1116.
-
Garcia-Bournissen F, Moghrabi A and Krajinovic M (2007) Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leukemia Res. 31(7) :1023-1025.
-
Brukner I, El-Ramahi R, Gorska-Flipot I, Krajinovic M and Labuda D (2007) An in vitro selection scheme for oligonucleotide probes to discriminate between closely related DNA sequences. Nucleic Acid Res. 35(9):e66.
-
Brukner I, El-Ramahi R, Sawicki J, Gorska-Flipot I, Krajinovic M and Labuda D (2007) Hybridization assay performed at ambient temperature fur typing high-rish human papillomaviruses. J Clin Virology 39(2) :113-8
-
Brukner I, Krajinovic M, Dascal A and Labuda D (2007) A protocol for the in vitro selection of specific oligonucleotide probes for high-resolution DNA typing. Nature Protocols 2: 2807-2814
-
Gorska-Flipot I, Sawicki J Krajinovic M, Labuda D, Brukner I, Rouleau D, Ghattas G,. Franco E and Coutlée F (2008). Newly isolated HPV97 related to HPV 18 and 45 is highly prevalent in HIV positive males in Montreal. Int J Cancer. 122:1195-7
-
Dulucq S, St-Onge G, gagné V., Labuda D, Sinnett D, Moghrabi A, Krajinovic M (2008) DNA variants in dihydrofolate reductase gene and outcome in childhood ALL. Blood. 111:3692-3670 (the article presented in the journal issue by editorial)
-
Joly Y, Sillon G., Silverstein T, Krajinovic M, Avard D (2008) Pharmacogenomics : Don’t forget children. Current Pharmacogenomics 6 :77-84.
-
Dulucq S, Bouchet S , Turcq B, Lippert E, Etienne G, Reiffers J , Molimard M , Krajinovic M, Mahon F-X (2008) Multidrug Resistance Gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukaemia. Blood 112:2024-20277
53). Krajinovic M. Brukner I., Iqbal O, Bender R., Joshi VA, John T, Tsao M-S, GL (2008) Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients. Personalized Medicine, 5:325-329.
-
Krajinovic M (2008) MTHFD1 gene: role in disease susceptibility and pharmacogenetics, Pharmacogenomics 9:829-832.
54) Ollivier M-L, Dubois M-F, Krajinovic M, Cossette P, Carmant L (2008): Risk factors for valproic acid resistance in childhood absence epilepsy. J. Epilepsy (submitted)
55) Ansari M, Lauzon-Joset J-F, Vachon M-F, Duval M, Théorèt Y, Champagne M, Krajinovic M (2008) Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Blood (submitted)
Published contributions to a collective work/book chapters/reviews (2003 – present)
-
Sinnett D, Mathonnet G, Meloche C, Moghrabi A, Labuda D and Krajinovic M (2003) Genetic determinants to childhood acute lymphoblastic leukemia. Recent Res Devel Haematol. 1:135-154.
-
Labuda D, Krajinovic M and Bourgeois S (2004) Allele specific oligonucleotide hybridization (ASO). Encyclopedia of Diagnostic Genomics and Proteomics, Marcel Dekker, New York; pp38-41.
-
Krajinovic M and Moghrabi A (2004) Pharmacogenetics of methotrexate. Pharmacogenomics 5:819-834.
-
Sinnett, D, Meloche C, Labuda D, Mathonnet G, Moghrabi A, Sabbagh A, Infante-Rivard C and Krajinovic M (2005) Genetic susceptibility to childhood acute lymphoblastic leukemia. Progress in Leukemia Research, Nova Science Publishers, Inc. New-York. pp. 1-31
-
Sinnett D, Labuda D, and Krajinovic M (2005) Challenges identifying genetic determinants of pediatric cancers – the childhood leukemia experience. Familial Cancer 5:35-47.
-
Sinnett D, N’Diaye N, Labuda D and Krajinovic M (2006) Genetic determinants of childhood leukemia. Bulletin du cancer. 93:857-865.
-
Ansari M and Krajinovic M (2007) Pharmacogenomic in cancer treatment: Defining genetic bases for interindividual differences in responses to chemotherapy. Curr Opin Pediatr. 19:15-22.
-
Ansari M and Krajinovic M (2007) Pharmacogenetics of acute leukemia. Pharmacogenomics. 8 :817-834.
12) Robaey P, Krajinovic M, Marcoux S and Moghrabi A (2008) : Pharmacogenetics of sensitivity to chemotherapy. Ment. Retard. Dev Disabil. Res. Rev. submitted.
13) Krajinovic M (2008): Pharmacogenetics of acute lymphoblastic leukemia in Advani A: Adult Acute Lymphocytic Leukemia: Biology and Treatment. Humana Press (submitted)
Invited presentations (2003 - present)
-
“Pharmacogenetics of ALL”, Hôpital Hôtel-Dieu, October 16, 2003.
-
"Pharmacogenetics of methotrexate", 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine, October 14-16, 2004, Hersinissos, Crete, Greece.
-
«Pharmacogénétique de la leucémie lymphoblastic aigue», Centre de Recherche, Hôpital Sainte-Justine, Ocotber 28, 2005.
-
« Pharmacogenetics of immunosuppressors », 1ere Journée de Pharmacologie clinique, Ste-Justine Hospital, June 2006.
-
“Pharmacogénétique de la leucémie lymphoblastic aigue”, Service d’hématologie, Hôpital Sainte-Justine, Montréal, April 2007.
-
« Pharmacogénétique et leucémie lymphoblastique aigue » 10eme Congres de BioACM, Université du Québec à Montréal, May 2007.
-
« Pharmacogenetics: principles and application », World University Service (WUS) Brain Gain Program, Belgrade, June 11-15, 2007.
-
“Pharmacogenetics of acute lymphoblastic leukemia”, The IX th World Conference on Clinical Pharmacology and Therapeutics, July 27–August 1, 2008, Québec City, Canada.
Grant Support Received
Organism
|
Title
|
Principal Applicant
|
Amount/
year
|
Period
|
Fondation de l’Hôpital Ste-Justine (Fonds d’installation)
|
Genetic modulation of therapeutic response
|
Maja Krajinovic
|
$50, 000
|
2000-2002
|
Centre de recherche, Hôpital Ste-Justine (thematic funds)
|
Genetic determinants of MTX associated neurotoxicity.
|
Krajinovic, M
|
$30,000
|
2001-2002
|
Centre de recherche, Hôpital Ste-Justine (thematic funds)
|
Mining the archives for genetic material. DNA extraction and whole genome amplification of hematologic smears from leukemic patients.
|
Infante-R, C
Krajinovic ,M
Damian, L
Sinnett, D
|
$52,000
|
2001-2002
|
Leukemia Research Fund of Canada (operating grant)
|
Genes relevant for methotrexate response and the risk of relapse in childhood acute lymphoblastic leukemia.
|
Krajinovic, M
|
$40,000
|
2001-2003
|
Canadian Institutes of Health Research (operating grant)
|
Genetic determinants of the MTX response in childhood ALL.
|
Krajinovic, M
|
$56,000
|
2002-2005
|
Cancer Research Society, Inc. (operating grant)
|
The role of functional polymorphisms in genes relevant for the corticosteroid response in the outcome of childhood acute lymphoblastic leukemia.
|
Krajinovic, M
|
$50,000
|
2002-2004
|
Canada Foundation for Innovation (infrastructure grant)
|
Set up of a laboratory for pharmacogenetics development.
|
Krajinovic, M
|
$524,000
|
2002
|
Société de la recherche sur le cancer inc.
|
The role of functional polymorphisms in genes relevant for the corticosteroid response in the outcome of childhood acute lymphoblastic leukemia
|
Krajinovic, M
|
$50,000
|
2002-2004
|
Centre de recherche pédiatrique de l’Hôpital Ste-Justine
|
Développement d’une nouvelle génération de sondes du diagnostic moléculaire obtenues par la sélection in vitro
|
Labuda, D Krajinovic, M
|
$10,000
|
2004-2005
|
Centre de recherche pédiatrique de l’Hôpital Ste-Justine
|
Whole genome amplification (WGA) des échantillons génomiques en péril
|
Krajinovic, M
|
$10,000
|
2004-2005
|
CIHR
|
Developing diagnostic tools through in vitro molecular evolution
|
Labuda, D Krajinovic, M Gorska-Flipot, I
|
$197,326
|
2004-2006
|
CIHR
|
Genetic determinants of the response to anticancer drugs in childhood acute lymphoblastic leukemia
|
Krajinovic, M
|
$57,184
|
2005-2006
|
Organism
|
Title
|
Principal Applicant
|
Amount/
year
|
Period
|
Centre de Recherche,
CHU Ste-Justine
|
Technological improvement for nucleic acid amplification from clinical samples
|
Krajinovic, M
|
$10,000
|
2006-2006
|
Savoy Fondation
|
Pharmacogenomics of refractory childhood absence epilepsy
|
Carmant, L
Krajinovic, M
|
$21,750
|
2006-2007
|
PDL BioPharma, Inc.
|
Polymorphisms and Busulfan Pharmacokinetic Study
|
Champagne, M
Duval, M
Krajinovic, M
Ansari, M
Théoret,Y
|
$32,000
|
2006-2007
|
Charles Bruneau Foundation
|
Methotrexate pharmacogenetics
|
Krajinovic, M
|
$50,000
|
2006-2007
|
The Leukemia & Lymphoma Society of Canada
|
Childhood ALL pharmacogenetics: defining genetic bases for inter-individual differences in therapeutic response
|
Krajinovic, M.
|
$50,000
|
2007-2008
|
CIHR (POP)
|
Optimization and validation of human papilloma virus probes obtained through in vitro molecular evolution
|
Labuda, D,
Krajinovic, M
Gorska-Flipot, I
|
$150,000
|
2007-2008
|
Centre d’excellence en Oncologie pédiatrique et en soins palliatifs
|
Volet pharmacogénétique du centre d'excellence
|
Krajinovic, M
|
$74, 000
|
2007-2010
|
Fondation Télémaques Suisse
|
Pharmacogénétique du Busulfan
|
Ansari, M
Krajinovic, M
|
$43,000
|
2007-2008
|
Fondation Charles Bruneau
|
Génétique, polymorphisme et cancer
|
Maja Krajinovic Yves Théoret, Jean-Christophe Fournet
|
$100,000
|
2008-2009
|
CIHR
|
The potential to optimise asthma treatment based on individual genetic predisposition to respond to major drugs classes used in therapy of asthma
|
Krajinovic, M
Laberge, S
Bérubé, D
|
$121,353
|
2006-2009
|
Annex 4.
Dostları ilə paylaş: |
